![Design Therapeutics, Inc. logo](/logos/DSGN.webp)
Design Therapeutics, Inc.
NASDAQ:DSGN
Overview | Financials
Company Name | Design Therapeutics, Inc. |
Symbol | DSGN |
Currency | USD |
Price | 4.67 |
Market Cap | 264,417,735 |
Dividend Yield | 0% |
52-week-range | 1.96 - 5.48 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Pratik Shah Ph.D. |
Website | https://www.designtx.com |
An error occurred while fetching data.
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD